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The HIV-1 envelope interacts with coreceptors CCR5 and CXCR4 in a dynamic, multi-step process, its
molecular details not clearly delineated. Use of CCR5 antagonists results in tropism shift and therapeutic
failure. Here we describe a novel approach using full-length patient-derived gp160 quasispecies libraries
cloned into HIV-1 molecular clones, their separation based on phenotypic tropism in vitro, and deep
sequencing of the resultant variants for structure-function analyses. Analysis of functionally validated
envelope sequences from patients who failed CCR5 antagonist therapy revealed determinants strongly
associated with coreceptor speciﬁcity, especially at the gp120-gp41 and gp41-gp41 interaction surfaces
that invite future research on the roles of subunit interaction and envelope trimer stability in coreceptor
usage. This study identiﬁes important structure-function relationships in HIV-1 envelope, and demon-
strates proof of concept for a new integrated analysis method that facilitates laboratory discovery of
resistant mutants to aid in development of other therapeutic agents.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Infection by human Immunodeﬁciency Virus Type 1 is initiated
by viral envelope trimer binding to the host cell receptor, CD4, and
subsequently one of the two coreceptors C-C Chemokine Receptor
Type 5 (CCR5) or C-X-C Chemokine Receptor Type 4 (CXCR4). A
series of step-wise, dynamic conformational changes occurs fol-
lowing the two binding events which culminates in viral and cell
membrane fusion, and release of the nucleocapsid core into the
host cell (Wilen et al., 2012; Berger, 1997). The ability of a virion to
bind either one or both chemokine receptors for entry has sig-
niﬁcant implications in disease pathogenesis, and affects treat-
ment options (Gorry and Ancuta, 2011). Although nearly all
founder / transmitter viruses are strictly CCR5-tropic (termed R5
virus), close to 50% of HIV-1 subtype B patients will spontaneously
develop CXCR4-using (X4) virus as the disease progresses, and the
presence of X4 virus correlates with a worse clinical prognosis
(Connor et al., 1997). This observation is thought to reﬂect the
bottleneck nature of HIV-1 transmission, a preferential targeting of
previously activated memory T lymphocytes in the early phase ofInc. This is an open access article u
hington University School of
MO 63110, USA.
).
Francisco, CA, USAinfection, and a selection pressure that drives HIV-1 infection of
naïve T cells late in the disease course when the majority of
memory T cells are depleted (Schuitemaker et al., 2011). The
process of coreceptor shift that otherwise naturally occurs with
disease progression can take an expedited course upon the
administration of a CCR5 antagonist antiretroviral drug (Moore
and Kuritzkes, 2009). This limits the therapeutic application of
CCR5 antagonists in patient management, and requires meticulous
tropism determination prior to administration of the drug (Hen-
rich and Kuritzkes, 2013; Ray and Doms, 2006).
Numerous studies examined the structural aspects of HIV-1
envelope and coreceptor interaction (Picard et al., 1997; Samson et
al., 1997; Siciliano et al., 1999; Pontow and Ratner, 2001). There has
been a continuing effort to determine the viral envelope protein
structure in its ligand-free, mature trimer conﬁguration, as well as
in complex with neutralizing antibodies (Kwong et al., 1998;
Poignard et al., 2001; Do Kwon et al., 2015). Recently, high-
resolution crystal structures of CCR5 and CXCR4 in complexes
with small molecular ligands, have been determined (Wu et al.,
2010; Saita et al., 2006; Tan et al., 2013). These ﬁndings shed light
on the molecular interaction between the envelope and cor-
eceptor. However, because the viral entry process is highly
dynamic and involves large conformational changes of a complex
macromolecular conglomeration, there are still large gaps in our
understanding at a molecular level. The Variable loop 3 (V3)
region has been shown to play a critical role in coreceptornder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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CCR5 or CXCR4 (Westervelt et al., 1992). Regions outside V3 have
been found to affect tropism as well, but it is less clear how they
affect the entry process (Pastore et al., 2006; Cashin et al., 2014;
Dobrowsky et al., 2013).
Currently, tropism determination approaches can be broadly
categorized as phenotypic or genotypic approaches. Phenotypic
testing, such as the Troﬁle assay, is primarily based on ex vivo
determination of tropism in established coreceptor expressing cell
lines, and has been the gold standard for tropism determination
(Low et al., 2009). Recent advances in Next-Generation Sequencing
(NGS) technologies have made genotypic tropism testing more
feasible and potentially a cheaper, faster, and more accurate
alternative to phenotypic methods (Prosperi et al., 2010; Archer et
al., 2012; Sede et al., 2014; Swenson et al., 2011; Tsibris et al.,
2009). The current challenge with the wide application of geno-
typic tropism testing lies in the ability to accurately predict trop-
ism based on amino acid sequences. Current algorithms such as
Geno2Pheno and PSSM focus exclusively on the V3 region
sequence for tropism prediction, and the outcome, though accu-
rate for CXCR4 utilization, has a high false positive rate, and limits
the application of CCR5 antagonist drug to patients who could
potentially beneﬁt from the therapy (Lengauer et al., 2007; Jensen
et al., 2003; Sirois et al., 2005). Therefore, it is important to better
understand the molecular determinants for CXCR4 usage and the
structure-function relationship of HIV-1 envelope, and use this
information to enhance the predictive power of the current
methods in clinical and computational studies (Cashin et al., 2014;
Thielen et al., 2011). In addition, new determinants critical for
CXCR4 usage can be attractive drug targets for development of
future entry inhibitors.
Given the challenge that there are a limited number of phe-
notypically validated envelope sequences, in which most of the
available sequences include only the V3 region, we devised a novel
comprehensive approach that combines phenotypic tropism
determination with NGS technologies, and applied it to study a
panel of samples from patients who failed a CCR5 inhibitor clinical
trial. By analyzing NGS data of phenotypically validated full-length
HIV-1 gp160 sequences, we identiﬁed key determinants outside
V3 that correlate with coreceptor use and CCR5 inhibitor
resistance.2. Materials and methods
2.1. Patient samples
HIV-1 envelope amplicons were obtained from participants in a
Vicriviroc (VCV) Phase II clinical trial (AIDS Clinical Trials Group
[ACTG] A5211; NCT00082498) (Gulick et al., 2007). Participant
selection and sample preparation were described previously (Tsi-
bris et al., 2009). Plasma samples were collected from study par-
ticipants who experienced virologic failure and had tropism
change by the phenotypic Troﬁle assay (Monogram Biosciences).
Pelleted virion RNA was used to prepared env cDNA. Envelope
amplicons were generated using previously reported primers
(Kirchherr et al., 2007):
Env1Atopo (50-CACCGGCTTAGGCATCTCCTATGGCAGGAAGAA-30)
FLenv2.2 (50-AGCTGGATCCGTCTCGAGATACTGCTCCCACCC-30)
2.2. Plasmid library generation
Patient envelope amplicons were cloned in frame into HIV-1
molecular clone pNL4-3.Luc.R–.E– (Dr. Nathaniel Landau, the NIH
AIDS Reagent Program) using Gibson AssemblysMaster Mix (New
England Biolabs) following the manufacturer's protocol (Connor etal., 1995; He et al., 1995). An AfeI site (AGCGCT) that does not alter
the amino acid sequence was introduced at nucleotide 5954 of
pNL4-3.Luc.R–.E– by site directed mutagenesis. A NotI site is pre-
sent in the vector at the 4th codon of nef, the position at which the
luciferase gene was inserted. The vector was linearized using AfeI
and NotI. The insert was prepared by PCR ampliﬁcation of the






The PCR was set up with Q5 High-Fidelity 2Master Mix (New
England Biolabs) following the manufacturer's protocol, and run
on a BioRad T100 thermal cycler (BioRad) using the following
conditions: 98 °C for 30 s; 15 cycles of 98 °C for 10 s, 55 °C for 20 s,
and 72 °C for 2 min; and 72 °C for 5 min. The PCR product included
ﬂanking regions of pNL4-3.Luc.R–.E–. The Gibson assembly reac-
tion was performed with an insert to vector ratio of 3:1 at 50 °C for
60 min. The assembly product was diluted 1:3 and electroporated
into ElectroMAX™ Stbl4™ competent cells (Thermo Fisher) in
1 mm cuvette at 1.2 kV, 25 mF, 200 ΩmA on BioRad MicroPulser™
(BioRad). Transformants were recovered in 1 mL of S.O.C. medium
by shaking at 30 °C for 90 min at 225 RPM, and plated on Luria-
Broth agar plates supplemented with 150 μg/mL of ampicillin
(Sigma-Aldrich).
Plasmid libraries of envelope amplicons were generated by
harvesting 106 plate-grown transformant colonies and extracting
plasmid DNA using QIAGEN Plasmid Plus Mega Kit (Qiagen).
Transformed stbl4 cells were plated on 150 mm ampicillin selec-
tion plates at 104 colonies per plate. The colonies were incubated
at 30 °C for 36 h before being harvested using a scraper. The har-
vested bacterial colonies were centrifuged at 6000 g at 4 °C for
15 min in JA-14 rotor in a J2-HS centrifuge (Beckman). Endotoxin-
free plasmid DNA libraries were prepared according to the Qiagen
kit protocol. Plasmid library DNA samples for Illumina sequencing
were prepared by restriction enzyme digestion using NotI and
AfeI, followed by agarose gel puriﬁcation of the 3 kb band corre-
sponding to the size of the insert envelope gene.
2.3. Cell lines
HEK 293T cells were maintained in Dulbecco's Modiﬁed Eagle's
Medium (DMEM) supplemented with 10% fetal bovine serum,
2 mM L-glutamine, 1 mM sodium pyruvate, and 1x antibacterial,
antimycotic solution (containing 100 U/mL penicillin, 100 μg/mL
streptomycin, and 250 ng/mL amphotericin B). U87.CD4 cells were
stably transfected with pBABE-CCR5-GFP or pBABE-CXCR4-GFP,
constructed as previously described, and maintained in DMEM
supplemented with 15% fetal bovine serum, 2 mM L-glutamine,
1 mM sodium pyruvate, 1x antibacterial, antimycotic solution,
0.2 mg/mL G418, and 1 μg/mL puromycin (Pontow and Ratner,
2001).
2.4. Virus production and passage
Replication-competent HIV-1 was produced in culture by
transfecting 15 μg of the molecular clone plasmid DNA into 4106
HEK 293T cells using TransITs-LT1 Transfection Reagent (Mirus).
The viral supernatant was harvested at 48–72 h post transfection
and passed through a 0.45 μm syringe ﬁlter to remove cell debris.
Freshly prepared viral stocks were passaged on U87.CD4.CCR5 and
U87.CD4.CXCR4 cells at low multiplicity of infection (MOI equal to
or less than 0.1), in the presence of 8 μg/mL DEAE dextran, as
previously described (Pontow and Ratner, 2001). U87.CD4.CCR5
and U87.CD4.CXCR4 cells were incubated with viral supernatant at
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and applying fresh media, infection proceeded for another 24 h to
allow for a single cycle of virus replication. The viral supernatant
was harvested from the infected U87 cells, number of infectious
particles quantiﬁed, and virus used in the next round of passage.
2.5. HIV-1 luciferase reporter-based titration assay
Viral stocks harvested from 293T or U87 cells were quantiﬁed
for infectivity on U87.CD4.CCR5 and U87.CD4.CXCR4 cells using
serial dilutions in culture media from 5 to 510-fold (Michael and
Kim, 1999). The diluted viral stocks were used to infect 104 U87
cells in 6 replicates in a 96-well plate in the presence of 8 μg/mL of
DEAE dextran. Infection was carried out by incubating the cells
with dilutions of viral stocks for 12 h, removing the virus, and
incubating for another 24 h in fresh media. Cells were harvested
24 h post-infection and lysed with 0.2% Triton-X 100 (Sigma-
Aldrich) in PBS. The cell lysates were read for luciferase activity on
Optocomp I luminometer (MGM Instruments). A result was scored
as positive if the relative light unit readout was more than
2 standard deviations over the mean of mock infected control
wells. The number of positive and negative wells were counted,
and used to compute tissue culture infectious units using the
Spearman-Karber formula.
2.6. Functional library DNA preparation
Functional libraries were prepared by PCR ampliﬁcation of the
envelope gene from integrated proviral DNA using genomic DNA of
infected U87.CD4.CCR5 and U87.CD4.CXCR4 cells, harvested 24 h
post infection using the DNeasy Blood & Tissue Kits (Qiagen)
according to the manufacturer's protocol for nucleated cells. To
include maximum number of quasispecies and to minimize PCR
introduced founder effects, the entire genomic DNA preparation
was used in multiple independent PCR runs using NL4-AfeI-EnvF
and NL4-NotI-EnvR primers, and the resultant PCR products were
pooled. To minimize ampliﬁcation bias introduced by varying
template copy number, between 400–500 ng of genomic DNA was
used as PCR template for each run, resulting in approximately
6000 copies of proviral genome per reaction, after adjusting for
MOI and cell number. The ﬁnal pooled PCR products were puriﬁed
on agarose gels and quantiﬁed on TAKE3 plates using Synergy H4
Hybrid Multi-Mode Microplate Reader (Bio-Tek).
2.7. Next generation sequencing (NGS)
DNA samples were submitted to the McDonnell Genome
Institute at Washington University in St. Louis, MO for library
construction and sequencing using HiSeq 2000 and/or Paciﬁc
Biosciences (Pac Bio) RS II. For amplicon and plasmid library
sequencing with Illumina HiSeq2000, a minimum of 100 ng DNA
per sample was used for library construction. The yield and size of
input DNA was determined by a HS Qubit assay for quantitation
(Invitrogen) and run on an Agilent Bioanalyzer 2100 (Agilent
Technologies). Small insert dual indexed Illumina paired end
libraries were constructed with the KAPA LTP Library Prep kit
(KAPA Biosystems). 100 ng of genomic DNA was fragmented using
the Covaris LE220 DNA Sonicator (Covaris) to a size range between
200–800 bp using the following settings: volume¼50 mL,
temperature¼4 °C, duty factor¼15%, peak incident power¼450,
cycle burst¼200, time¼130 s. The Illumina ligations were ampli-
ﬁed in eight 50 uL reactions and were ampliﬁed with 10 PCR
cycles. Libraries were fractionated on the LabChip XT using the
DNA 750 chip (Perkin Elmer) collecting a 575 bp fraction with aþ/
 5% covariance, followed by an AMPure XP bead puriﬁcation to
remove residual small fragments. Each fraction/library wasassessed for concentration and size to determine molarity using
the HS Qubit assay and the Agilent BioAnalyzer High Sensitivity
DNA Assay. The concentration of each library fraction was veriﬁed
through qPCR according to the manufacturer's protocol (Kapa
Biosystems) to produce cluster counts appropriate for the Illumina
HiSeq2000 platform. The libraries were pooled in equal molar
ratios and loaded on 1 lane of the HiSeq2000 platform utilizing a
2101 bp recipe according to the manufacturer's recommenda-
tions (Illumina).
Functional libraries of 3 kb in length were sequenced with
HiSeq2000 as well as Pac Bio RS II. A minimum of 2 μg of func-
tional library env PCR product per sample was submitted for Pac
Bio library construction using SMRTBell™ Template Preparation
Kit (Paciﬁc Biosciences) following the manufacturer's protocol.
Library construction input was 750 ng per library. Each sample
was run on a single SMRT cell on the PacBio RS II platform using
P6v2/C4 chemistry and 240 min movie length.
2.8. NGS data analysis
Illumina datasets were quality controlled by performing
adaptor trimming, quality trimming, complexity screening, and
length ﬁltering using in-house codes. The amplicon and plasmid
library Illumina datasets were mapped, using BWA (Li and Durbin,
2009) or Bowtie2 (Langmead and Salzberg, 2012), to sample-
speciﬁc full-length reference sequences, which were pre-
determined by Sanger-sequencing of single clones. Pac Bio data-
sets of the functional libraries were quality trimmed using the
SMRT Portal system to extract the high-quality Reads-of-Inserts
(ROIs). The ROIs were aligned to sample-speciﬁc references using
BWA-MEM. Reads that span the entire V3 region were extracted
and numerated, assuming every individual read represents a sin-
gle DNA molecule in the sequencing process. Rare sequences that
were occurring at single-digit read level, visibly different from V3
and likely arising from mapping error and frame-shift translation
were manually removed. Single Nucleotide Polymorphism (SNP)
analysis was performed using GATK Haplotype Caller (https://
www.broadinstitute.org/gatk/).
2.9. Phylogenetic and statistical analysis
Hierarchical clustering was performed based on Euclidean
distance matrices and visualized using GENE-E (http://www.
broadinstitute.org/cancer/software/GENE-E/) or iTOF (http://itol.
embl.de/). V3 loop consensus sequences from two functional
clusterings and their signiﬁcantly different amino acid positions
were computed and visualized using IceLogo (http://iomics.ugent.
be/icelogoserver/index.html). The statistical signiﬁcances of the
differences in entropy at every nucleotide position between two
samples were determined by Student's t-test.
2.10. Deep sequence data sets
Raw sequence ﬁles from this study will be deposited in the
NCBI Short Read Archive at http://www.ncbi.nlm.nih.gov/sra
under BioProject ID PRJNA317236; accession numbers: SAMN0-
4633238-04633241.3. Results
3.1. Evaluation of HIV-1 patient samples by deep sequencing
HIV-1 patient samples were collected from eight study subjects
at two time points on ACTG A5211 Phase II study of Vicriviroc
(VCV) (Table 1). Based on the original Troﬁle in vitro phenotypic
Table 1
Longitudinal changes of HIV-1 envelope tropism in VCV treated patients.
aSubject ID Sample ID Time (weeks) R5-RLUb X4-RLUb Tropismc
1 1.1 0 593008 86 R5
1.2 2 139491 185312 DM
2 2.1 0 7360 129 R5
2.2 8 6260 2034 DM
3 3.1 0 774210 388 DMd
3.2 24 223785 1178193 DM
4 4.1 0 434886 76 R5
4.2 32 6627 117574 DM
5 5.1 0 37210 66 R5
5.2 8 50461 78889 DM
6 6.1 0 511349 1920 DM
6.2 8 124983 173363 DM
7 7.1 0 90578 63 R5
7.2 8 8211 9836 DM
8 8.1 0 391164 73 R5
8.2 2 1789 151040 DM
a Subject: HIV-1 patients who experienced virological failure (deﬁned as
smaller than 1 log10 viral load decrease at or after week 16 by protocol) in a
Vicriviroc phase IIb clinical trial.
b RLU: Relative Light Units by luciferase-based Troﬁles assay on CCR5 (R5) or
CXCR4 (X4) expressing cell lines.
c Tropism: the ability of the virus to utilize R5 and/or X4 for viral entry.
d DM: dual/mixed tropism. Dual tropism: the ability to utilize both R5 and X4
for entry; mixed tropism: coexistence of viral species that can use either R5 or X4
coreceptor for entry.
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only R5 viruses before VCV treatment (Time point 1 at Week 0). At
the second time point, where the subject experienced protocol-
deﬁned virologic failure (less than 1 log10 decrease of HIV-1 RNA
level at or after Week 16), plasma env amplicons demonstrated the
ability to utilize CXCR4 for entry, and their tropismwas designated
as dual-mixed (DM). The time elapsed between the ﬁrst and sec-
ond time points varied among the study subjects from 2 to
32 weeks.Fig. 1. (A) Schematic diagram of the experimental design. Patient derived envelope qu
NL4.3Env-lucþ reporter vector (plasmid libraries) and expressed in 293T cells as replicati
The functionally validated env quasispecies (functional libraries) were prepared by po
genomic DNA of the infected cells. The three sets of libraries were sequenced by Illumin
(B) SNP based clustering analysis of 16 amplicon libraries based on Illumina sequenci
sequence using GATK. A Euclidean-distance based clustering of 16 amplicon libraries wTo understand HIV-1 env sequence characteristics with respect
to their function, we devised a novel experimental scheme that
allowed high-throughput phenotypic tropism determination fol-
lowed by deep sequencing of functionally validated env libraries
(Fig. 1A). By generating a heterogeneous library of replication
competent HIV-1 virions that contained a diverse set of env qua-
sispecies from patient samples, we physically separated the env
quasispecies based on their tropism by passaging the virus on
CCR5-or CXCR4-expressing U87.CD4 cells. The subset of env var-
iants extracted from the proviral DNA in the infected CCR5-or
CXCR4-expressing cells was termed a functional library, and their
sequences were determined on both Illumina and Pac Bio plat-
forms. To conﬁrm that the sequence heterogeneity was not lost
during the process of molecular cloning, we analyzed the original
patient amplicon samples (named amplicon libraries) and the
intermediate plasmid library containing one million colonies using
Illumina sequencing.
A clustering analysis using single nucleotide polymorphism
(SNP) information of the sixteen amplicon libraries positioned the
pair of samples from each study subject on a single branch of a
Euclidean-distance tree (Fig. 1B). The clustering pattern was con-
sistent with the known sample identities, and conﬁrmed that deep
sequencing data can be used to accurately categorize HIV-1 env
samples based on their sequence signatures.
3.2. Sequence diversity of patient amplicon libraries over time
We ﬁrst analyzed the V3 coding sequence, as it is the primary
determinant of coreceptor use. We found the patient samples were
diverse and heterogeneous, to a similar degree as previous studies
had reported, by counting the number and frequencies of different
variants in the sample (AM 07:56 20-04-2016Archer et al., 2012;
Tsibris et al., 2009). An in-depth population level variant analysis
was performed by extracting and enumerating reads that span the
entire 33 codons between the two cysteine residues at theasispecies amplicons (amplicon libraries) were cloned into replication competent
on competent virions that were used to infect CCR5 and CXCR4 expressing cell lines.
lymerase-chain reaction of the proviral DNA using env-speciﬁc primers from the
a HiSeq2000; functional libraries were also sequenced by Paciﬁc Biosciences RS II.
ng of the full-length env gene. SNPs were called with HXB2 env as the reference
as constructed using 843 SNPs present in all samples.
Fig. 2. Population analysis of V3 loop sequences and frequencies in amplicon and plasmid libraries. (A) Sample 1.1 amplicon library (AL), (B) Sample 1.2 AL, (C) Sample 2.1 AL,
(D) Sample 2.2 AL, (E) Sample 1.1 plasmid library (PL), and (F) Sample 1.2 PL. (G) A summary table compares amplicon libraries versus plasmid libraries for Sample 1.1 and 1.2.
Total V3 reads are representative of the depth of sequencing. A clonal control env from Sample 1.2 was prepared and sequenced in parallel. For amplicon and plasmid libraries
in (A)–(F), unique V3 variants and their respective frequencies are represented as slices on a pie chart. The same color in different libraries represents a common V3 variant
found in both libraries. For amplicon libraries in (A)–(D), the sequences and proportions of the most abundant V3 loop variants are listed. The coreceptor usage predicted by
Geno2Pheno[corecptor] is shown for every sequence. The signiﬁcance level of the prediction was set at 2% and 5.75% False-Positive Rate (FPR) as the optimized cut-offs based
on clinical data from the MOTIVATE study (FPRo0.2%: X4-capable; FPR45.75%, X4-incapable.) *For the 5th most abundant variant in Sample 2.2, the V3 sequence is
predicted to be X4-capable with a FPR of 5.4%, which falls in between the optimized cut-off values.
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comes from one DNA molecule, which comes from one quasis-
pecies in the infected individual. Thus, by enumerating the non-
redundant reads, we captured a snapshot of the quasispecies
landscape in the patient at the time of sampling (Tsibris et al.,
2009). To control for PCR introduced mutations and sequence
errors, we performed PCR ampliﬁcation and deep sequencing of a
clonal control env (data not shown). We detected 233 distinct non-
redundant variants out of 31,989 extracted V3 reads, with the most
abundant variant that was identical to the pre-determined
sequence occurring 30,967 times (96.8%). None of the remaining
232 variants exceeded 0.05% of the total population. Therefore, we
concluded that the error rate was low and applied a cut-off ﬁlter at
0.05% level, or at single read level to the sixteen amplicon library
datasets to remove possible artifact reads.
From the sixteen samples coming from eight study subjects, we
selected four samples from two subjects (Samples 1 and 2, Table 1)
for the population level variant analysis (Fig. 2). We chose to focus
on these two subjects because their samples demonstrated dif-
ferent lengths of time for coreceptor shift. Subject 1 showed high
R5-tropic viral activity at baseline and comparable R5-and X4-
tropic activity in only two weeks, whereas samples from Subject
2 remained predominantly R5-tropic at Week 0 and Week 8, but
also showed signiﬁcantly increased X4-tropism at the second time
point, based on the luciferase assay readings (Table 1). Examina-
tion of the variant proﬁle revealed distinct quasispecies compo-
sitions in these two subjects (Fig. 2A–D).
The viral population in Subject 1 before VCV treatment existed
as one dominant variant that accounted for 62.6% of the total
population (Fig. 2A Variant 1), a less dominant variant at 17.2%
level (Fig. 2A Variant 2), and numerous rare variants that occurred
in single-digit counts and less than 1% of all V3 reads. On the other
hand, the second time point sample (1.2) contained 2 major var-
iants, at 46.1% and 38.8% abundance, respectively (Fig. 2B Variant
1 and 2), followed by a minor variant at 1.4% level, and rare var-
iants at less than 1% level. Contrary to previous studies and our
expectation that a pre-existing CXCR4-using variant at Week
0 expanded under drug selection to become a major variant at
Week 2, we did not detect the major variants from Sample 1.2
(Fig. 2B Variant 1 and 2) in Sample 1.1. Instead, a completely dif-
ferent and CXCR4-using population emerged and rapidly took over
in two weeks, resulting in escape from the VCV therapy and vir-
ologic failure in Subject 1.
Different from Subject 1, Subject 2 showed dynamic expansion
and contraction of variants over the 8 weeks of VCV treatment. At
Week 0, the subject harbored multiple major variants, each at
47.6%, 20.6%, and 8.1% of the total, respectively (Fig. 2C Variant 1–
3), all of which were predicted to use CCR5 exclusively for viral
entry based on the Geno2Pheno[coreceptor] predictive algorithm.
Some minor R5-tropic variants from Sample 2.1, present at abun-
dances of 5.9%, 4.7% and 1.4% (Fig. 2C Variants 4–6), respectively,
persisted and expanded through the treatment and were detected
again at Week 8 at relative abundances of 15.7%, 20.9%, and 9.9%
(Fig. 2D Variants 3, 2, and 4). The most abundant variant in Sample
2.2, accounting for 25.7% of total reads (Fig. 2D Variant 1), arose
from a rare variant at 0.47% level in Sample 2.1. In contrast, the two
most abundant variants present at 47.6% and 20.6% frequency in
Sample 2.1 were completely eliminated from the circulation.
Overall, Subject 2 largely retained its population diversity over
8 weeks, with expansion of pre-existing CXCR4-using variants and
maintenance of several variants using CCR5 only in face of VCV
treatment.3.3. Evaluation of plasmid and functional library variants
To phenotypically test a large number of env quasispecies, we
generated plasmid libraries of complete NL4.3.Lucþ molecular
clones containing env sequences from the two samples of Subject
1. The plasmid libraries were sequenced with Illumina HiSeq to
ensure that the original quasispecies diversity was retained by the
cloning process. We conducted the population level variant ana-
lysis on the plasmid library sequencing datasets and discovered
almost identical variant distributions, with a maximal change of
major variant abundance at 3.3% of the total V3 reads (Fig. 2E
compared to 2A, 2F compared to 2B, and 2G).
Functional libraries were generated by passaging plasmid
libraries 1.1 and 1.2, through U87.CD4.CCR5 or U87.CD4.CXCR4
cells at low MOI (r0.1) for two or three passages each consisting
of a single-cycle infection. A functional library control was also
generated by passage of the single env control in parallel. The four
functional libraries obtained through this procedure included two
independent passages of Sample 1.1 on CCR5-expressing cells
(thus named 1.1_R5_FL1 and 1.1_R5_FL2), passage of Sample 1.2 on
CXCR4-expressing cells (named 1.2_X4_FL), and a control passage
of the single clone isolate from Sample 1.2 on CXCR4-expressing
cells (named 1.2_Ctrl_X4). The functional libraries were sequenced
by Pac Bio RSII in addition to Illumina, so that the linkage infor-
mation between SNPs longer than 100 bases apart could be
studied.
High-quality Reads-of-Inserts (ROIs) of the 4 functional librar-
ies from the Pac Bio platform were generated. A total of 26,046
ROIs were obtained passed a quality ﬁlter of 99% per base accuracy,
including 4667 ROIs from 1.1_R5_FL1, 8707 ROIs from 1.1_R5_FL2,
6783 ROIs from 1.2_X4_FL, and 5889 ROIs from 1.2_Ctrl_X4. The
average length for ROIs is 2260 bp, with the majority of ROI at
2.9 kb, consistent with the input fragment size. All ROIs were
generated from circular consensus sequencing of 10 passes or
more, resulting in a low error rate per base and high quality output
sequencing reads.
Analysis of variants at the population level in the four func-
tional libraries was performed to understand the quasispecies
proﬁle across the envelope variable regions (Fig. 3). Insufﬁcient
reads from the V1 region were extracted to permit meaningful
analysis, likely due to the incompatibility between our stringent
read extraction criteria and the presence of large insertions and
deletions in this region. Therefore, we focused on the V2 through
V5 regions instead. To control for the errors introduced by PCR,
virus passaging, and sequencing procedures, we analyzed the
clonal control 1.2_Ctrl_X4 functional library at V2 through V5,
and detected minimal amounts of deviant variants across the ﬁve
regions (data not shown). Overall, in the three remaining librar-
ies, the analysis revealed distinct quasispecies landscapes for R5
versus X4 variants. The two biological replicates, 1.1_R5_FL1 and
1.1_R5_FL2, were highly consistent in terms of the major variants
and their abundances across V3–V5 regions, conﬁrming that the
passaging method was a reliable and reproducible approach to
capture functionally validated quasispecies (Fig. 3, Columns 1 and
2). In R5-tropic functional libraries from 1.1, one major clone and
one minor clone were found in V2, whereas V3 and V4 primarily
show one major clone. The V5 regions are more diverse and
consist of multiple variants each at lower abundances. In the
X4-tropic functional library from 1.2, V2 through V4 consistently
show two major clones, while V5 shows only one dominant
clone.
Examination of the quasispecies proﬁles in the V3 region of the
functional libraries show that they were highly similar to those of
the starting amplicon libraries (Fig. 2A–B, Fig. 3). The most abun-
dant variants in Sample 1.1 and 1.2 amplicon libraries were present
in the functional libraries, suggesting the V3 variants observed in
Fig. 3. Functional library population level variant analysis at env variable regions in Patient 1. Reads extracted from variable regions V2 (HXB2 gp160 amino acid 158–186d),
V3 (297–330), V4 (385–418) and V5 (460–469) from functional libraries 1.1_R5_FL1, 1.1_R5_FL2, and 1.2_X4_FL1 are visualized in pie charts with the most abundant variants
annotated. 1.1_R5_FL1 and 1.1_R5_FL2 are biological replicates prepared from Sample 1.1 passaged on U87.CD4.CCR5 cells. 1.2_X4_FL1 was prepared from Sample 1.2 pas-
saged on U87.CD4.CXCR4 cells. Sequencing data shown were generated on the PacBio RS II system. Individual reads that span through the entire region between the given
coordinates were selected, trimmed, and translated into amino acid sequences. Quasispecies are represented by non-redundant amino acid sequences and are color-coded
across libraries in the same row. V3 variants are represented in same colors in Row 2 as in Fig. 2A–B, and E–F.
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quasispecies. The two most abundant variants in Sample 1.1
(Fig. 2A Variants 1 and 2), as well as the three most abundant
variants in Sample 1.2 (Fig. 2B Variants 1–3) were detected at
comparable proportions in the functional libraries (Fig. 3, Row 2).
Interestingly, a rare variant in the original amplicon library of
Sample 1.1 at only 0.13% level (Fig. 2A and B) expanded throughthe passaging to become the third most abundant variant in
1.1_R5_FL1 at 3.5%, and the second most abundant variant in
1.1_R5_FL2 at 7.1% (Fig. 3, Row 2). This suggested that the
enrichment and contraction of variants in the functional library
were not stochastic events. The ability of certain variants but not
the others to persist through the passaging process was directly




2.1_AL 2.1_PL 2.2_AL 2.2_PL
 
Fig. 4. Amplicon and plasmid library population level variant analysis at env variable regions in Patient 2. Reads extracted from variable regions V2 (HXB2 gp160 amino acid
158–186d), V4 (385–418) and V5 (460–469) from amplicon (AL) and plasmid libraries (PL) of 2.1 and 2.2 are visualized in pie charts with the most abundant variants
annotated. 2.1_AL and 2.1_PL are technical replicates prepared from Sample 2.1. 2.2_AL and 2.2_PL are technical replicates prepared from Sample 2.2. Sequencing data shown
were generated on HiSeq 2000 system. Individual reads that span through the entire region between the given coordinates were selected and translated into amino acid
sequences. Quasispecies are represented by non-redundant amino acid sequences and are color-coded across libraries in the same row. These pie charts were analyzed
together with V3 variants represented in Fig. 2C–D.
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centration of the reporter cell lines.
Similar variant population analyses through V2–V5 regions
were performed with Amplicon (ALs) and Plasmid Libraries (PLs)
for Samples 2.1 and 2.2 (Fig. 4). Comparing the ALs and PLs (Fig. 4,
Column 1 versus Column 2, and Column 3 versus Column 4), it is
worth noting that the major variants are mostly consistent in
terms of their identity and frequency, offering additional evidence
that the cloning process to generate PL from AL does not sig-
niﬁcantly alter the quasispecies representation in the community.
Interestingly, in Subject 2, the V2 region showed a signiﬁcant
change of the variant populations (represented as change of colors
in the pie chart from 2.1 to 2.2), similar to the dynamics observed
in V3 (Fig. 4, Row 1, Fig. 2C–D). On the other hand, the V4 and V5
region variant distributions remained largely constant from
before-treatment sample 2.1 to post-treatment sample 2.2 (Fig. 4,
Rows 2 and 3). This is in contrast with Subject 1, where we
observed emergence of new variants and drastic changes in the
population landscape during treatment (Figs 2–4). Through
population level variant analysis on two subjects, we conclude that
the two individuals have undergone different viral population
shifts over the course of treatment.3.4. Characterization of V3 variants based on sequence signature
shows consistency with functional tropism
To dissect the sequence signature of HIV-1 env isolates and its
relationship with the coreceptor binding function, we generated a
hierarchical cluster, based on a Euclidean-distance matrix, using
167 V3 variants from all 4 functional libraries (Fig. 5A). The
sequence-based clustering separated the variants into two groups
that coincided almost perfectly with their function, except for
three variants from CCR5 functional libraries that were grouped
with variants from CXCR4 libraries (Fig. 5A, circled in green). These
three variants were predicted by the Geno2Pheno algorithm to be
able to also use CXCR4 for entry, suggesting that these were rare
variants before treatment that could utilize CXCR4 for entry but
did not expand upon VCV treatment likely due to low ﬁtness.
Similar clustering analysis was performed using V3 sequences
from functionally validated single clones of Sample 2.2 (Fig. 5B). To
cross-validate the unexpected AL deep sequencing result that
shows R5-only V3 variants in Subject 2 post-treatment based on
Geno2Pheno[coreceptor] prediction, we functionally tested 15
full-length env single clones and conﬁrmed that approximately
half of them are R5-tropic only (Fig. 2C–D). A V3 region clustering
analysis showed that sequence similarities placed the 15 variants
Fig. 5. (A) Hierarchical clustering analysis of 167 V3 variants from four functional libraries. (1.1_R5_FL1, 1.1_R5_FL2, 1.2_X4_FL1, and 1.2_Ctrl_X4). The presence and absence
of variants is indicated using the color coded squares. Highly abundant variants are indicated by arrows. Green circles denote variants a, b, and c from 1.1_R5_FL1 and/or
1.1_R5_FL2, which were grouped in Cluster 2 and predicted to use CXCR4 by Geno2Pheno[coreceptor] (G2P). Sequences for the three circled variants are: a –
CTRPNNNTRKGIHIGPGRAVYVAEKIIGNIRQAHC; b – CIRPNNNTRKGIHIGPGRAVYVAEKIIGNIRKAYC; c – CTRPNNNTRKGIHIGPGRAVYVAEKIIGNIRKAYC. (B) Hierarchical cluster-
ing analysis of 15 single clone V3 sequences from Sample 2.2 with experimentally determined differential usage of R5 and X4 coreceptors. The single clones are labeled as
(sample #) (clone #) (tropism). The R5 tropic clones and dual tropic clones are clearly separately on two branches by sequence similarity, except for Clone 45 that was tested
dual-tropic but clustered with other R5 tropic clones. G2P predicted both clone #45 and #13 to be R5-tropic, though #45 is only slightly over the cutoff at 2–5.74% false-
positive rate (FPR) based on MOTIVATE trial. Sequences for the two most closely related but functional discordant clones are: 2.2 45 dual –
CVRPNNNTRKSINMGPGRVFHTSEIIGDVRQAHC (G2P FPR 5.9%)2.2 13 R5 – CVRPSNNTRKSINMGPGRVFHASEIIGDVRQAHC (G2P FPR 9.5%).
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The dual-tropic clones are grouped together and away from the
R5-tropic clones, except for one clone (Clone #45) that showed
more similarity to R5-tropic sequences. This is consistent with our
observation in the V3 clustering analysis from Subject 1 FLs to
show that V3 sequence based clustering can usually correctly
predict function. However, the misplacement of clone #45 alsohighlights its limitations, as other regions outside V3 that con-
tribute to coreceptor speciﬁcity are not taken into consideration in
this analysis.
We generated consensus sequences of all the variants in each
cluster with IceLogo2, taking into consideration their respective
abundance, and identiﬁed amino acid positions differentiating
cluster 1 and cluster 2 at a signiﬁcance level of Po0.001 (Fig. 6A–
Fig. 6. (A) ConsensusV3 sequences of Cluster 1 and 2 of Patient 1 V3 variants. (B) Signiﬁcantly different amino acid residues (Po0.001) between the V3 consensus sequences
of Cluster 1 and 2. (C) Consensus V3 sequence for 7 dual-tropic and 8 R5 tropic single clones from Patient 2 Sample 2.2. (D) Differentiating amino acid residues between the
consensus V3 sequences. Due to small sample sizes, the differences are not statistically signiﬁcant. Critical residues at the 11th and 24th/25th positions are highlighted with
red arrows.
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each other based on the Logo plots, and were distinct from those
in CXCR4 functional libraries. Cluster 1 showed a high degree of
conservation, which was reﬂected by a major variant that
accounted for over 80% of the population. Cluster 2 showed a clear
divergence at Position 31, which was representative of two major
variants at 43.5% and 50.2%, respectively (Fig. 5A). Altogether, we
identiﬁed nine positions (Positions 2, 20, 22, 23, 24, 25, 31, 32, and
34) in the V3 region with signiﬁcantly different amino acid resi-
dues, that were likely responsible for the differential functionality
to engage CCR5 versus CXCR4 as entry coreceptor (Fig. 5B). Con-
sistent with our observation, these positions and amino acid
residues have been previously reported in HIV-1 Subtype B and C
patient samples to correlate with CCR5 or dual-tropism (Masso
and Vaisman, 2010; Rodriguez et al., 2015). In addition, at the 25thposition in Cluster 1 was a negatively charged glutamic acid,
whereas occupying the same position in Cluster 2 was a positively
charged lysine, which was indicative of CXCR4-usage by the 11/25
Rule (Jensen and van't Wout, 2003).
A similar analysis was performed for the two functional groups
from Sample 2.2 and the ﬁndings were consistent with those from
Subject 1 (Fig. 6C–D). As compared to Subject 1, we observed, in
Subject 2, diversity at more positions (Positions 10, 22, 28, 29, and
31 in R5-tropic group, and Positions 9, 11–14, 18, 19, 21–24, and 29
in dual-tropic group). This result is likely due to the small sample
sizes (8 for R5-tropic group and 7 for dual-tropic group), and also
the diverse V3 landscape in Subject 2, as previously mentioned
(Fig. 6C, Fig. 2D). Residues that differ between the two groups
were identiﬁed although they failed to reach statistical sig-
niﬁcance (Fig. 6D). Residue changes at Positions 11 and 24 (instead
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2.2 compared to those from Sample 1.2) were also noted, in par-
ticular the charge ﬂip from glutamic acid to arginine or lysine at
Position 24. Through the clustering and consensus analysis from
2 subjects, we demonstrated that categorizing HIV-1 V3 variants
by sequence similarity created clusters that were mostly con-
sistent with their function. Moreover, these results conﬁrmed that
the V3 region is a critical modality for coreceptor tropism
determination.
3.5. Important regions outside V3 that correlate with envelope
tropism
We analyzed the full env gene to examine other determinants
of tropism beyond the V3 region using Shannon's entropy
approach and SNP analysis for Subject 1 and 2 datasets (Figs. 7-8).
Shannon's entropy analysis examines cross-sectional diversity at a
given position, with higher entropy values responding to more
diversity. We utilized entropy analysis to compare the entropy
values at each nucleotide position between pre-treatment and
post-treatment amplicon libraries of Subjects 1 and 2, to explore
regions that were undergoing an increase or decrease in diversity
due to VCV selection.
Overall, in Subject 1, Sample 1.1 had higher entropy across the
length of the env gene than Sample 1.2, as demonstrated by 120
positions in Sample 1.1 and only 51 positions in Sample 1.2 that
have statistically above-background entropy values whenFig. 7. Shannon's entropy analysis of amplicon libraries (AL) from Sample 1.1 and 1.2. (A
and 1.2 AL. A total of 120 positions in Sample 1.1 (blue) and 51 positions in Sample 1.2 (re
control dataset (not shown), by one-tailed Student's t-test, po0.0001. (B) Entropy diffe
1.2 AL. At 17 positions (shown in Table 2), the entropy values in Sample 1.1 differ signicompared with the clonal control dataset (Fig. 7A, po0.0001).
This suggested that the viral quasispecies population before VCV
treatment was more heterogeneous than the quasispecies present
after treatment. The treatment likely selected for a dominant drug-
resistant variant, or a group of closely related resistant variants,
thus, driving down the overall diversity in the population. The
decrease in entropy from Samples 1.1 to 1.2 occurred along the
length of env, as represented by the entropy difference map
(Fig. 7B). However, speciﬁc locations showed an increase in
entropy, in particular at HR1/HR2 regions and the cytoplasmic
domain of gp41, suggesting diversifying selection at those loci
(Table 2).
In Subject 2, Samples 2.1 and 2.2 showed less difference in
entropy than the samples from Subject 1 (Fig. 8). We identiﬁed 98
positions in Sample 2.1 and 79 positions in Sample 2.2 that have
entropy values signiﬁcantly over zero (Fig. 8A, po0.0001). In
contrast to the reduction in entropy over treatment in Subject 1,
the entropy values showed an overall increase over the course of
treatment in Subject 2, suggesting diversifying selection on the
quasispecies population in Subject 2 (Fig. 8B). This is consistent
with our previous observation that Subject 2 had more diverse
variant landscapes than Subject 1 (Fig. 2A–D). Five positions
between Sample 2.1 and 2.2 experienced signiﬁcant changes in
entropy, all of these positions are located in gp120 (Table 2).
SNP analysis on the four functional library datasets using GATK
program identiﬁed 106 SNPs in the entire env gene with reference
to the control single clone sequence from Sample 1.2. Clustering of) Absolute entropy values at each nucleotide position along the env genes for 1.1 AL
d) have entropy values signiﬁcantly over background entropy values in the 1.2 clonal
rence at each nucleotide position by subtracting the values of 1.1 AL from that of
ﬁcantly from those in Sample 1.2, by two-tailed Student's t-test, po0.0001.
Table 2
Positions in env that correlate with coreceptor usage.
AAa SNPb ΔEntc Ptd Signiﬁcance Ref












V1 134a 0.96 1
V2 168 K/R 2 gp120-gp120 Pancera et al. (2014)
170 0.92 2
178 T/K 2
C2 229 K/R 2 C228-C239; N230
glycosite
Leonard et al. (1990)




V3 295 0.36 2 N295 glycosite; DC-
SIGN bs
Hong et al. (2007)









C3 344 Q/R 2
351 E/K 1
354 K/E/R 2
V4 412 E/D 1
C4 421 R/K 1 Coreceptor bs Korber and Gnanakaran
(2009)
424 V/I 1 R54 speciﬁc site
425 N/K 1 CD4 main/side chain
bs
Zhou et al. (2010)
432 K/T 1 CD4 main chain bs
440 N/R/S 1,
2
R54 speciﬁc site Korber and Gnanakaran
(2009)
442 -0.87 1 Coreceptor bs
444 S/R 1 C378-C445 Leonard et al. (1990)
V5 465d R/K 1
467 0.42 2
C5 476 K/R 1,
2
CD4 side chain bs Zhou et al. (2010)
490 Q/K 1 gp120-gp41 Pancera et al. (2014)
496 L/V -0.71 1
500 K/M -0.92 1
502 K/R 2
503 0.76 1
Table 2 (continued )
AAa SNPb ΔEntc Ptd Signiﬁcance Ref
FP 514a M/T/I 1
518 V/M 1
525 T/A 1 gp120-gp41 Pancera et al. (2014)
FPPR 534 A/S 1 gp120-gp41, gp41-
gp41
535 0.82 1 gp41-gp41
541 T/A 1 gp120-gp41, gp41-
gp41
543 R/Q 1 gp120-gp41
HR1 547 G/V 2 gp41-gp41
556 M/L 2
596 0.99 1 gp120-gp41 Pancera et al. (2014)
621 E/D 1
HR2 633 0.31 1 gp120-gp41 Pancera et al. (2014)
CD 724 0.98 1
749 0.99 1
802 0.50 1
A total of 54 residues that correlate with coreceptor usage are identiﬁed from
2 patients (Patient 1: 38; Patient 2: 20; both: 4).
SP: signal peptide; FP: fusion peptide; bs: binding site.
a AA: amino acid positions are numbered based on HXB2.
b SNP: Positions showing 450% switch from reference to alternative allele in
SNP analysis are annotated as ref/alt/alt/alt. Reference alleles are based on 1.2 and
2.2 single clone control sequences for Patient 1 and 2 respectively.
c ΔEntropy¼post treatment entropy – before treatment entropy. Positive
value: increase in entropy/diversity; negative value: decrease in entropy. Changes
in entropy are statistically signiﬁcant, with p values o0.0001 by two-tailed t-
test.
d Pt. indicates the patient number of the datasets from which a particular
residue is identiﬁed by SNP and/or entropy analysis.
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patterns reﬂects the functional categorization of the four libraries,
with 1.1_R5_FL1 and 1.1_R5_FL2 on a single branch, and away from
1.2_X4_FL and 1.2_Ctrl_X4 on a different branch (Fig. 9A). To
identify SNPs that could differentiate CCR5 versus CXCR4 cor-
eceptor usage, we focused on 23 non-synonymous loci (annotated
in the red boxes) that were completely different in CCR5-using
groups than in CXCR4-using groups, including 22 loci outside the
V3 region. Among the 23 positions identiﬁed, 4 positions (N325,
K421, I424, and S440) were previously known to strongly affect
coreceptor binding and speciﬁcity, and 3 positions (N425, K432,
and R476) were reported to be CD4 binding residues (Kwong et al.,
1998; Korber and Gnanakaran, 2009; Zhou et al., 2010). Sixteen
positions identiﬁed through the SNP analysis have not previously
been identiﬁed to have a function in receptor or coreceptor
binding, although many in this unknown category (L86, N87, K490,
V496, K500, A525, S534, A541, and Q543) were found to be
involved with gp120 – gp41 interaction (Table 2, Fig. 10) (Korber
and Gnanakaran, 2009; Zhou et al., 2010; Pancera et al., 2014;
Hong et al., 2007; Leonard et al., 1990). This ﬁnding suggests a role
of gp120-gp41 interaction in coreceptor speciﬁcity, potentially by
affecting trimer stability, entry dynamics and thus fusion efﬁ-
ciency following coreceptor binding. A recently published study
also identiﬁed residues 432 and 500 for their importance in trimer
stability, highlighting the possibility that these interaction surface
Fig. 8. Shannon's entropy analysis of Sample 2.1 and 2.2. (A) Absolute entropy values at each nucleotide position along the env genes for 2.1 and 2.2. A total of 98 positions in
Sample 2.1 (blue) and 79 positions in Sample 1.2 (red) have entropy values signiﬁcantly over zero, by one-tailed Student's t-test, po0.0001. (B) Entropy difference at each
nucleotide position by subtracting the values of 2.1 from that of 2.2. At 5 positions (shown in Table 2), the entropy values in Sample 1.1 differ signiﬁcantly from those in
Sample 1.2, by two-tailed Student's t-test, po0.0001.
J. Zhang et al. / Virology 494 (2016) 198–214210residues might play a functional role in the overall envelope trimer
structure (Guenaga et al., 2015).
Similar SNP analysis was performed with Subject 2 amplicon
and plasmid library datasets, based on the single clone analysis
results that approximately 50% of post-treatment variants in
Sample 2.2 can utilize CXCR4 (Fig. 9B, Fig. 5B). To identify residues
that associate with R5-versus X4-usage, we focused on 15 non-
synonymous loci (annotated in the red boxes) that showed at least
50% difference in reference allele frequency between pre-
treatment and post-treatment samples. Taken together with the
5 positions identiﬁed in the entropy analysis, the total 20 loci
identiﬁed include 4 previously reported coreceptor binding spe-
ciﬁc sites (N300, I309, N325, and S440), 1 in the CD4 binding site
(R476), and 3 positions within or adjacent to glycosylation sites
(N229, N295, and N300). Thirteen positions were not previously
reported to have a function in coreceptor binding (Table 2).
Interestingly, 4 loci out of the 13 are located on an interaction
surface between gp120-gp41, gp41-gp41, or gp120-gp120 and
could potentially affect envelope trimer stability.
Comparing these residues that associate with differential cor-
eceptor use from Subjects 1 and 2, we identiﬁed 4 loci that are
common to both subjects (V87, N325, S440, and R476). Among the
4 common residues, N325 and S440 were previously reported to
be coreceptor binding speciﬁc sites inside and outside V3
respectively, R476 is within the CD4 site chain binding site, and
V87 is a gp120-gp41 contact site within one subunit of the trimer.Besides the residues in common between the two subjects, many
other loci from the two subjects fall into similar functional
domains of CD4 interaction, coreceptor binding, and interaction
between subunits in the timer, even though they are not at the
exact same position. This evidence strongly suggests that there are
common pathways that affect coreceptor shift. Besides coreceptor
binding and CD4 binding pathways that have been extensively
studied, residues that play a role in envelope structural stability
potentially inﬂuence coreceptor usage.
For visualization of the critical regions that correlated with
coreceptor speciﬁcity, annotation was performed on the ligand-
free native envelope gp140 trimer crystal structure (PDB ID: 4MJZ)
(Fig. 10). A group of residues (colored red) that were previously
reported to be coreceptor-speciﬁc is located near the envelope-
coreceptor binding interface and likely to affect binding via direct
contact with extracellular regions of the coreceptors. A second
group of residues (colored magenta) located near the CD4 binding
site is likely to affect coreceptor usage via interaction with CD4
and subsequent induction of a conformational change into an open
trimer. A third group (colored blue and green) that is located at
contact surfaces between gp120-gp41, gp41-gp41 and gp120-
gp120 is likely to affect tropism via more global mechanisms,
such as alteration of the overall conﬁguration of envelope trimer
or its dynamic conformational change upon CD4 and/or coreceptor
engagement.
Fig. 9. Clustering analysis based on SNP loci allele frequency of full length env datasets from Patient 1 and 2. (A) Four functional libraries (FL) from Sample 1.1 and 1.2 were
clustered by overall similarity between the four samples based on 106 SNP loci allele frequencies. A single clone control (1.2_Ctrl_X4) sequence was used as reference. A total
of 37 differentiating SNPs are found in the regions outline by the red boxes (residues showing over 75% shift from reference to alternative alleles), among which 24 SNPs at
23 codons lead to non-synonymous amino acid substitution (shown in Table 2). Only 1 out of the 24 SNPs falls within the V3 loop region. (B) Amplicon libraries (ALs) and
plasmid libraries (PLs) from Sample 2.1 and 2.2 were clustered by similarity between the four datasets based on 112 SNP loci allele frequencies. A single clone sequence from
2.2 was used as reference. A total of 22 differentiating SNPs are identiﬁed in the regions outlined by the red boxes (residues showing over 50% shift from reference to
alternative alleles), among which 16 SNPs lead to non-synonymous amino acid substitutions (shown in Table 2). Two out of the 16 SNPs fall within the V3 region.
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In this study, we developed a comprehensive phenotypic assay
platform in combination with NGS technologies to analyze HIV-1
quasispecies diversity and tropism before and after emergence of
drug resistance in vivo. This novel approach employed a tissue-
culture based library passaging method and allowed us to study in
unprecedented depth and breadth the quasispecies population
and their structure-function relationship by generating sequences
from phenotypically validated env variants. The output data pro-
vided new insights into important features of HIV-1 env that are
implicated in coreceptor interaction, speciﬁcally the residues that
are located at the trimer interaction surface and could potentially
affect envelope spike stability and conformational dynamics. These
ﬁndings shed light on new drug targets for HIV-1 entry inhibitor
development. In addition, the experimental approach can poten-
tially be adapted for the study of drug resistance development in
order to identify new therapeutic agents, especially for develop-
ment of unusual combinations of drug resistant mutations that
requires phenotypic characterization of new and complex
genotypes.
Quality control of the sequencing data is extremely important
in NGS-based studies to ensure the accuracy and relevance of the
ﬁnal conclusion. In our study, we performed all the experimental
procedures including PCR, cloning, infection, passaging, Illumina
and Pac Bio sequencing, reads ﬁltering, and the ﬁnal analysis with
a clonal control of known nucleotide sequence in parallel. There-
fore, we could calculate the cumulative error rate of PCR and
cloning errors, passaging artifacts, and sequencing errors at every
step of the process by analyzing the single clone control dataset
and apply an appropriate ﬁlter level based on the control errorrate. Notably, the combined error rate from PCR-induced sub-
stitution and sequencing in our experience were markedly lower
than previously reported, likely reﬂecting improved ﬁdelity
(4100 of Taq) of the PCR polymerase and a newer generation
sequencing method (Tsibris et al., 2009).
A potential source of error that we could not control for using
the single clone method is strand-switching (recombination)
during the PCR, transfection and infection process. Salazar-
Gonzalez and coworkers demonstrated the extent of bulk PCR
induced sample skewing including nucleotide substitutions and
recombination by comparing the single clone sequences from bulk
PCR to those obtained through Single-Genome Ampliﬁcation
approach (Salazar-Gonzalez et al., 2008). We estimated the effects
of RT-PCR and second round PCR on amplicon libraries based on
previously published information on patient samples that came
from the same cohort as ours. The recombined clones resulted
from PCR accounted for less than 0.15% of the total population, and
did not signiﬁcantly affect the proportions of major variants as
demonstrated previously (Tsibris et al., 2009). For subsequent PCR-
based ampliﬁcations to generate the plasmid and functional
libraries, we used a high-ﬁdelity high-processivity polymerase,
low cycle number (15 cycles), and high primer concentration to
suppress the level of recombination as described by Smyth and
coworkers (Smyth et al., 2010). In order to minimize recombina-
tion events and production of genotype-phenotype mismatched
virions from cells infected by more than one viral particle over the
infection process, we performed the passages using an MOI of
0.1 or less. By Poisson distribution, through one passaging process
at MOI of 0.1, less than 5% of virions come from multiply infected
cells; whereas after three rounds of passaging, 0.02% of virions
results from multiply infected cells that may undergo
Fig. 10. Residues within and outside the V3 loop differentiate R5-versus X4-usage. (A) Representation on the gp140 SOSIP ligand-free trimer structure (PDB ID: 4ZMJ) of 16
loci differentiating CCR5 from CXCR4 utilization. The front view shows a trimeric spike with gp41 on the top and gp120 at the bottom. The bottom view shows the
perspective looking up from the host cell membrane. The subunits are shown in surface model, with gp120 in light grey and gp41 in dark grey in two of the three subunits.
The third subunit is colored by region as the following: light blue, gp41 ectodomain; pink, gp120; pale-yellow, V1/V2 loop; orange, V3 loop; and magenta, CD4 binding site
(CD4bs). The differentiating loci are color-coded based on their previously reported known functional status. Red: coreceptor binding or speciﬁc site; magenta: CD4 contact
residues; blue: intra-subunit gp120-gp41 interaction site; green: inter-subunit gp120-gp41 and gp41-gp41 interaction site; teal: no previously reported function in viral
entry. (B) Enlarged front and back views of the 16 differentiating residues on a cartoon representation of gp140 subunit. Residues are annotated and grouped based on their
functional status and color coded in the same manner as in (B). Four residues identiﬁed in both Patient 1 and 2 (87, 325, 440, and 476) are shown in bold with asterisk (*).
J. Zhang et al. / Virology 494 (2016) 198–214212recombination during reverse-transcription, or carry mismatched
genomic RNA compared to the envelope protein on the surface. In
addition, we also utilized the amplicon and plasmid library dataset
as baseline for the functional library variant analysis, and removed
55 out of 220 V3 variants that did not exist in the ﬁrst two
libraries, therefore eliminating the majority of recombination
errors and passaging artifacts. Biological replicates of Sample1.1 on
CCR5-expressing cell lines served as another layer of control and
conﬁrmed that our approach is robust and reproducible. Finally,
genotypic and phenotypic tropism analysis of 97 single clones from
Subject 1 and 2 amplicon libraries conﬁrmed the sequences and
tropism of all the dominant V3 variants identiﬁed by deep sequen-
cing, thus demonstrating the accuracy of sequence and tropism
determination by this new integrated approach (data not shown).
The quasispecies landscape at the two snapshots through time
in two study subjects alluded to different evolutionary pathways.Through analysis of V3 variants in amplicon libraries from Subject
1, we were unable to detect a minor variant at Week 0 that
expanded into a major variant at Week 2 despite multiple rounds
of sequencing and extensive depths of coverage at 600 to
6000 . If a minor CXCR4-tropic variant was present at very low
frequency (less than 3.2% of the total population) in the circula-
tion, it would not be detected by the current approach. Therefore,
a plausible origin of the X4-using variants may be from one or a
few very low frequency pre-treatment variants. Consistent with
the “ﬁtness valley” model of coreceptor shift, we detected few
intermediate variants from CCR5-only to CXCR4-using genotypes,
as they are thought to be less ﬁt and are quickly selected out (Poon
et al., 2012; da Silva and Wyatt, 2014). On the contrary, Subject
2 demonstrated a typical dynamic quasispecies population shift
under the selection pressure from the CCR5 antagonist, during
which rare pre-existing CXCR4-using clones expanded and
J. Zhang et al. / Virology 494 (2016) 198–214 213susceptible clones declined. Interestingly, several major variants
predicted to be R5-tropic only in Sample 2.1 had unexpectedly
persisted and expanded over treatment, perhaps by acquiring
resistance through an alternative mechanism, such as binding to
the CCR5-VCV complex for entry (Moore and Kuritzkes, 2009).
One limitation of this study is the sampling method. We were
unable to access quasispecies residing in lymph nodes and latently
infected cells, as the patient samples were collected and prepared
from free circulating virions in the plasma. Since HIV-1 quasis-
pecies at these sanctuary sites are often sheltered from anti-
retroviral therapy, or are exposed to a lower dose and sub-optimal
combination of antiretroviral drugs, the virus may continue to
replicate at low levels and develop resistance progressively in a
step-wise fashion, even when the treatment appears fully sup-
pressive (Moreno-Gamez et al., 2015; Rothenberger et al., 2015).
Some of the viral quasispecies that eventually escape treatment
and migrate to the blood are predicted to harbor multiple muta-
tions, consistent with our observations. A recent study also shows
that proviral populations in peripheral blood mononuclear cells
are different from those in lymphoid organs and in latently
infected memory cells; the variants in circulation are often
defective or less ﬁt (Cohn et al., 2015). Since we are just beginning
to understand these tissue-localized HIV quasispecies, more stu-
dies are needed to examine the evolutionary process in local
lymphoid tissues and latently infected reservoirs to elucidate how
they contribute to coreceptor shift and resistance development.
Another caveat with the analysis to identify important residues
for coreceptor shift is a small sample size. We were examining two
subjects from a clinical trial. While we found common pathways
and trends that would affect coreceptor usage, due to the small
sample size we cannot completely eliminate founder effect in this
analysis. Approximately 40% of all the residues (22 loci out of 54
total loci from two patients combined) have no previously repor-
ted functional connection to coreceptor usage or subunit interac-
tion. Many of these could be passenger mutations that occur
during the viral evolutionary process in these individuals, and do
not have a role in drug resistance. While it is reassuring to see
common residues identiﬁed in both patients and more residues
that fall into similar categories, future studies are needed to
examine more patients and to experimentally validate these resi-
dues in vitro to establish a clear functional connection to cor-
eceptor speciﬁcity.
Overall, this study employed a novel experimental approach to
characterize phenotypically validated envelope sequences with
conﬁdence, by coupling a phenotypic passaging assay with deep
sequencing analysis. We identiﬁed three regions outside V3 that
associate with coreceptor shift in the context of VCV selection,
including the C4 region, CD4 binding site, and the interaction
surface between gp120-gp41 and between gp41 subunits. A
majority of the residues identiﬁed in the ﬁrst two regions are
consistent with and conﬁrm previously published data on cor-
eceptor speciﬁcity and viral entry, while a new subset of mutations
at the gp120-gp41 interaction site alludes to interesting new
hypotheses for the mechanism of coreceptor shift, even though it
is based on the observation on a single patient before and after
CCR5 antagonist treatment. One could speculate and investigate
into possibilities such as fusion efﬁciency enhancement or global
envelope quaternary structure modulations through the gp120-
gp41 interaction to compensate for weak CXCR4 binding and
confer X4-tropism.
Last but not least, this experimental approach would poten-
tially be applicable for drug resistant mutation discovery and
research in the context of other therapeutic agents. This study
serves as a proof of concept in the context of tropism testing and
CCR5 antagonist treatment. By coupling phenotypic and pheno-
typic testing, this integrative approach harnesses the power ofdeep sequencing analysis to understand the process of drug
resistant development over the viral quasispecies evolution
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